Cargando…
Transitioning peanut oral immunotherapy to clinical practice
Peanut allergy is on the rise in industrialized countries, affecting 1%–4.5% of children and generally persisting into adulthood. It is associated with a risk of severe anaphylaxis and is one of the major causes of food allergy-induced deaths. Health-related quality of life is significantly impaired...
Autores principales: | Lazizi, S., Labrosse, R., Graham, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458956/ https://www.ncbi.nlm.nih.gov/pubmed/36092278 http://dx.doi.org/10.3389/falgy.2022.974250 |
Ejemplares similares
-
Transitioning from epicutaneous to oral peanut immunotherapy
por: Wong, Lauren, et al.
Publicado: (2023) -
Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand
por: Wanniang, Naphisabet, et al.
Publicado: (2023) -
Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond
por: Chua, Gilbert T., et al.
Publicado: (2021) -
Peanut butter feeding induces oral tolerance in genetically diverse collaborative cross mice
por: Immormino, Robert M., et al.
Publicado: (2023) -
Peanut Oral Immunotherapy: a Current Perspective
por: Patrawala, Meera, et al.
Publicado: (2020)